lantern-pharma-announces-significant-positive-preclinical-data-in-pancreatic-cancer-with-drug-candidate-lp-184

Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184

 

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, announced today positive new data from its ongoing pancreatic cancer collaboration with the Pancreatic Cancer Institute at Fox Chase Cancer Center. Preclinical data demonstrated that the drug candidate, LP-184, demonstrated significant and rapid pancreatic tumor shrinkage, by over 90%, in in-vivo mouse models in 8 weeks. In comparison, the tumors in the untreated mice grew by over eleven-fold in volume during the same 8 week period.

Additional positive data on the efficacy and potency of LP-184 was gathered from 6 pancreatic cancer cell lines, and an additional 5 patient-derived xenograft (PDX) ex-vivo tumor models. Significant reduction of cancer cells and cancer cell growth was observed across all pancreatic cancer cell lines and PDX models that were tested in the study with IC50 values being in the nanomolar range (45-270 nM). These data and observations are being prepared for peer-reviewed publications, manuscripts and scientific conferences. Data from this study will be used to power future insights and analysis provided by Lantern’s A.I. platform, RADR® , in addition to further enhancing the signature of response for LP-184 in pancreatic cancers. Lantern believes this to be a significant positive advancement for LP-184 in targeted pancreatic cancers and plans to advance the collaboration with Fox Chase Cancer Center into the next phase.

CRISPR knockout data confirmed the importance of PTGR1 in LP-184 cytotoxicity in pancreatic cancer, and validates the RADR-generated hypothesis that PTGR1 plays the leading role in orchestrating responsiveness of tumors to LP-184. The research conducted at Fox Chase Cancer Center leveraged CRISPR editing to silence the gene PTGR1 in pancreatic cancer cells — this resulted in virtually no-response by the pancreatic cancer cells to the drug. Those pancreatic cancer cells with PTGR1 expression (untouched by gene-editing) had heightened response to LP-184 causing cell death and IC50 values in the sub-100nM range. Lantern believes that using a defined genetic signature for patient selection can enhance the likelihood of clinical trial success and focus future clinical trials on those patients that will benefit most from the therapy.

The research has been conducted in collaboration with Dr. Igor Astsaturov, an established, NCI funded, physician scientist and co-leader of the Marvin & Conchetta Greenberg Pancreatic Cancer Institute at Fox Chase Cancer Center. Results demonstrated that LP-184 significantly and rapidly shrunk pancreatic cancer xenografts in mice, and after treatment with once weekly dosing at 3 mg/kg for 8 weeks, no tumors were present in 1 of 4 treated mice and in 3 of 4 mice the average size of remaining tumors was approximately 7% of the original tumor and 146-fold smaller than the untreated tumors.

Additional research was conducted with Dr. Astsaturov to further confirm the increased sensitivity to LP-184 in tumors that had damage to DNA repair pathways. It was observed that pancreatic tumors that harbored genetic alternations in the following DNA repair pathways — NER (nucleotide excision repair) and HR (homologous recombination) — had 2-fold increased sensitivity to LP-184. This observed data has implications in increasing the potential number of pancreatic cancer patients that can benefit from LP-184, and also in confirming prior Lantern research focused on aiming this drug-candidate at other cancers that have DNA repair pathway mutations. These could be mutations or deficiencies in genes such as: BRCA1, BRCA2, ATM, ATR, ERCC2, ERCC3, ERCC4, ERCC5, ERCC6, FANCD2, RAD51 and PALB2.

“These data mechanistically validate LP-184’s potential as a synthetic lethal agent in many HRD (homologous recombination deficient) and NERD (nucleotide excision repair deficient) cancers.” stated Dr. Astsaturov.  “As a result, these data may be highly supportive of a future role for LP-184 in a genetically-defined subset of pancreatic cancer.”

Pancreatic cancer is an orphan disease and has a five-year survival rate of 7.9%. This means that only approximately 8 in 100 people will have survived for five years and beyond. The 10-year survival rate of the disease is 1%, meaning only approximately 1 in 100 people survive 10 years and beyond. Pancreatic cancer has among the lowest 5-year survival rate of any of the 22 common cancers. GLOBOCAN estimates that for pancreatic cancer there are approximately 490,000 thousand new cases of pancreatic cancer globally, with over 62,000 occurring in North America annually. Targeting a specific subset of pancreatic cancer patients that are genetically defined has the potential to increase beneficial therapeutic options for patients and may ultimately improve survival for those with this cancer.

“We are highly encouraged by the results of this preclinical research and look forward to reporting the full results at future scientific conferences and in publications,” noted Dr. Kishor Bhatia, Lantern’s Chief Scientific Officer. “The study observed the significant and targeted anti-tumor effects of LP-184, even in pancreatic cancers that were resistant to standard-of-care drugs. Moreover, we also validated through the elegant work done with Dr. Astsaturov’s lab, by use of CRISPR-editing, that PTGR1 does directly link to the anti-tumor activity of LP-184. We expect that we will be able to exploit this biomarker mechanism in various tumors beyond pancreatic in the future.”

Lantern believes that LP-184 acts by damaging DNA selectively in tumors that express high levels of the enzyme PTGR1 – which occurs in several solid tumors. Analysis with Lantern’s data platform, RADR®, indicated that 35-40% of pancreatic cancer transcriptomes in clinical databases have elevated PTGR1 expression. Lantern has also begun discussions on the design of first-in-human clinical studies for LP-184 in collaboration with Dr. Igor Astsaturov and other key opinion leaders in the pancreatic cancer treatment landscape. Lantern plans on initiating IND (Investigational New Drug) application enabling animal studies later this year, and Phase 1 human trials following the filing of a future IND application.

lantern-pharma-announces-scientific-&-preclinical-data-indicating-blood-brain-barrier-permeability-for-drug-candidate-lp-184-in-glioblastoma-and-potentially-other-cns-cancers

Lantern Pharma Announces Scientific & Preclinical Data Indicating Blood Brain Barrier Permeability for Drug Candidate LP-184 in Glioblastoma and Potentially Other CNS Cancers

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform to transform drug discovery and development, and identify patients who will benefit from its portfolio of targeted oncology therapeutics, announced today new scientific data that substantiates blood brain barrier permeability (BBB) for its drug candidate LP-184. LP-184 is being targeted for treating Glioblastoma Multiforme (GBM), an aggressive malignant form of brain cancer that comprises about 52% of all primary malignant brain tumors according to the American Association of Neurological Surgeons.  GBM has a median survival rate of only 15 months and ranks among the most aggressive of human cancers. It is considered an orphan disease for which there is no cure. The global GBM treatment market is projected to reach $3.3 billion by 2024, according to GlobalData, with the U.S. representing the largest market.

The ability of a drug candidate to cross the blood brain barrier is of critical importance in treatment outcomes for CNS and brain cancers. Many drugs fail in clinical trials because of their low blood brain barrier permeability.  Lantern’s A.I. engine along with algorithms tuned to predict BBB permeability played an important role in helping determine which CNS cancers and which genomically-defined subtypes of CNS cancer should be prioritized for development.

The current standard of care for GBM consists of de-bulking surgery followed by combined treatments with fractionated ionizing radiation (IR) and the DNA alkylating agent temozolomide (TMZ). The effectiveness of standard therapy with TMZ is limited because the response of GBM to TMZ is dependent upon the expression of the DNA repair enzymatic protein, O6-alkylguanine DNA alkyltransferase (MGMT).  Over the period of treatment, tumors can evolve and begin to overexpress MGMT and therefore become largely resistant to TMZ. At the stage of GBM relapse and recurrence, no effective therapy strategies currently exist. LP-184 has a different mechanism of action relative to TMZ and has not demonstrated limitations due to MGMT levels, the enzymatic protein associated with resistance to TMZ in GBM and gliomas.

LP-184 works by causing DNA damage in cancer cells that can be repaired exclusively by the nucleotide excision repair (NER) pathway, while TMZ causes damage that can be repaired exclusively by the base excision repair pathway (BER). These approaches to killing tumor cells may be complementary and represent the potential for future combination therapy applications. Using in-silico tools, and also generating further in-vitro data from both neuronal cell-plates, and neurospheres, LP-184 demonstrated permeability that was in line with TMZ and other therapies being used in GBM today, while also demonstrating nano-molar potency.

Panna Sharma, CEO of Lantern Pharma, stated: “This data is extremely significant as it provides evidence that opens up a range of brain cancers with high clinical need that we should pursue, and also provides evidence that our RADR® platform is working as was designed. Our mission is to transform and accelerate the cancer drug development process.  If we can compress the time to clinical trials, and de-risk LP-184, we can save years of research and millions of dollars in developing treatments for GBM and potentially other CNS and brain cancers.”

Mr. Sharma continued, “As part of our development strategy we will be providing updates on new collaborations and research studies with leading research and translational cancer centers to help us further validate our findings and guide the ideal clinical usage of the compound in GBM. Based on data from our RADR platform, the blood brain barrier profile validation, and information on the genomics that seem to drive response to LP-184 we are now targeting a broader range of central nervous system cancers, including cancers that metastasize to the brain, and pediatric brain tumors.”

lantern-pharma-announces-upcoming-conference-presentations

Lantern Pharma Announces Upcoming Conference Presentations

 

Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) platform to transform the pace, risk and cost of oncology drug discovery and development, and identify patients who will benefit from its targeted oncology drug candidates, announced that Panna Sharma, CEO and President, will participate in the following investor events in December:

  1. Diamond Equity Research Emerging Growth Invitational
    Date/time: December 1, 2020 at 12:20 pm ET
    Zoom Link for Live Event: https://us02web.zoom.us/webinar/register/WN_2S0ftHykTdSY_7HJCjGZAQ

  2. hubXchange Virtual US East Coast AI in Drug Discovery Xchange
    Date/time: December 2, 2020 at 12:20 pm ET
    Location: https://www.hub-xchange.com/ai-in-drug-discovery-2020

  3. 2020 Benzinga Global Small Cap Conference
    Date/time: December 9, 2020 at 3:30 p.m. ET
    Zoom Link for Live Event: https://us02web.zoom.us/j/89571252065

All meetings and presentations will be held virtually. Investors and media interested in meeting with Panna Sharma should contact Marek Ciszewski, J.D., at: [email protected] or +1.628.777.3167. Registered conference attendees may also request meetings through the respective conference registration system.